FISH – NTRK 1 GENE REARRANGEMENT ASSAY Test
Test Name: FISH – NTRK 1 GENE REARRANGEMENT ASSAY Test
Components: NTRK1 (1q21.3)
Price: 1400.0 AED
Sample Condition: Submit formalin fixed paraffin embedded tissue block or three 4 micron sections on Poly L Lysine coated slides. Ship at room temperature. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Report Delivery: Sample Daily by 6 pm; Report 4 Working days
Method: FISH
Test type: Cancer
Doctor: Oncologist
Test Department: CYTOGENETICS
Pre Test Information: Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Test Details
The FISH – NTRK 1 gene rearrangement assay test is a diagnostic tool used to detect rearrangements in the NTRK 1 gene. This gene encodes for the neurotrophic receptor tyrosine kinase 1 protein, which plays a role in the development and function of nerve cells.
Rearrangements in the NTRK 1 gene can result in the fusion of the NTRK 1 gene with another gene, leading to the production of a fusion protein. This fusion protein can drive the growth and survival of cancer cells, and has been implicated in certain types of cancer, such as certain types of lung cancer, colorectal cancer, and thyroid cancer.
The FISH – NTRK 1 gene rearrangement assay test uses a technique called fluorescence in situ hybridization (FISH) to detect these gene rearrangements. FISH involves labeling specific DNA sequences with fluorescent probes and then hybridizing them to the patient’s tumor sample. If a rearrangement has occurred in the NTRK 1 gene, the fluorescent signals will be rearranged compared to the normal gene.
This test is typically performed on tumor samples obtained through a biopsy or surgical resection. It can help identify patients who may benefit from targeted therapies that specifically target the NTRK 1 fusion protein. These targeted therapies have shown promising results in clinical trials and have been approved by the FDA for certain cancer types with NTRK 1 gene rearrangements.
Overall, the FISH – NTRK 1 gene rearrangement assay test is an important tool in the diagnosis and treatment of certain types of cancer, as it can help identify patients who may benefit from targeted therapies.
| Test Name | FISH – NTRK 1 GENE REARRANGEMENT ASSAY Test |
|---|---|
| Components | *NTRK1 (1q21.3) |
| Price | 1400.0 AED |
| Sample Condition | Submit formalin fixed paraffin embedded tissue block or three 4 micron sections on Poly L Lysine coated slides. Ship at room temperature. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
| Report Delivery | Sample Daily by 6 pm; Report 4 Working days |
| Method | FISH |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | CYTOGENETICS |
| Pre Test Information | Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory. |
| Test Details | The FISH – NTRK 1 gene rearrangement assay test is a diagnostic tool used to detect rearrangements in the NTRK 1 gene. This gene encodes for the neurotrophic receptor tyrosine kinase 1 protein, which plays a role in the development and function of nerve cells. Rearrangements in the NTRK 1 gene can result in the fusion of the NTRK 1 gene with another gene, leading to the production of a fusion protein. This fusion protein can drive the growth and survival of cancer cells, and has been implicated in certain types of cancer, such as certain types of lung cancer, colorectal cancer, and thyroid cancer. The FISH – NTRK 1 gene rearrangement assay test uses a technique called fluorescence in situ hybridization (FISH) to detect these gene rearrangements. FISH involves labeling specific DNA sequences with fluorescent probes and then hybridizing them to the patient’s tumor sample. If a rearrangement has occurred in the NTRK 1 gene, the fluorescent signals will be rearranged compared to the normal gene. This test is typically performed on tumor samples obtained through a biopsy or surgical resection. It can help identify patients who may benefit from targeted therapies that specifically target the NTRK 1 fusion protein. These targeted therapies have shown promising results in clinical trials and have been approved by the FDA for certain cancer types with NTRK 1 gene rearrangements. Overall, the FISH – NTRK 1 gene rearrangement assay test is an important tool in the diagnosis and treatment of certain types of cancer, as it can help identify patients who may benefit from targeted therapies. |
